US2018079741A1PendingUtilityA1
Process for producing heterocyclic compound
Assignee: TAKEDA PHARMACEUTICALS COMPANY LTDPriority: Mar 14, 2014Filed: Oct 18, 2017Published: Mar 22, 2018
Est. expiryMar 14, 2034(~7.6 yrs left)· nominal 20-yr term from priority
B01J 2531/842B01J 2531/822C07D 211/78B01J 31/2409A61P 43/00B01J 31/2226A61P 3/10B01J 2531/0263B01J 2531/824C07F 17/02B01J 2231/645B01J 2531/821C07D 211/60B01J 31/2452B01J 2531/827C07F 9/5027B01J 2531/0205C07F 15/0046B01J 2540/225C07B 2200/07B01J 2531/0266C07D 401/04B01J 31/2295
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a method of efficiently producing an optically active 6-(3-aminopiperidin-1-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivative. The optically active piperidine-3-carboxamide or a derivative thereof, which is obtained by subjecting 1,4,5,6-tetrahydropyridine-3-carboxamide or a derivative thereof to an asymmetric reduction in the presence of a catalyst, is used as an intermediate.
Claims
exact text as granted — not AI-modified1 . A method of producing an optically active form of a compound represented by the formula:
wherein
R 1 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or a protecting group;
R 2 , R 3 and R 4 are independently a hydrogen atom or a substituent;
R 5 and R 6 are independently a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or
R 1 and R 2 in combination, R 2 and R 3 in combination, R 3 and R 4 in combination, or R 5 and R 6 in combination optionally form a 5- to 8-membered ring together with the adjacent atoms, and the carbon atom marked with * is an asymmetric carbon atom, or a salt thereof, which comprises subjecting a compound represented by the formula:
wherein each symbol is as defined above,
or a salt thereof, to a hydrogenation reaction in the presence of an organic metal complex.
2 . The method according to claim 1 , wherein the organic metal complex is a transition metal complex.
3 . The method according to claim 2 , wherein the transition metal complex is a ruthenium complex.
4 . The method according to claim 3 , wherein the ruthenium complex is represented by the formula:
[Ru(OCOR a ) 2 L*] (VIII)
wherein R a is an optionally substituted C 1-3 alkyl group; and L a is a diphosphine ligand.
5 . The method according to claim 1 , wherein the hydrogenation reaction is performed in the presence of an alkali metal halide or a compound represented by the formula:
wherein
R A , R B , R C and R D are independently a hydrogen atom, or an optionally substituted hydrocarbon group; and
X is a halogen atom.
6 . A compound represented by the formula:
wherein R is an optionally substituted hydrocarbon group.
7 . An optically active form of a compound represented by the formula:
wherein
R is an optionally substituted hydrocarbon group, and
the carbon atom marked with * is an asymmetric carbon atom.Join the waitlist — get patent alerts
Track US2018079741A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.